Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children
about
A review of malaria vaccine clinical projects based on the WHO rainbow tablePhase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectorsA plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.Genetic diversity and population structure of genes encoding vaccine candidate antigens of Plasmodium vivax.Particle-based platforms for malaria vaccines.Strategies for intranasal delivery of vaccinesPre-erythrocytic malaria vaccines: identifying the targets.Experience and challenges from clinical trials with malaria vaccines in AfricaProgress and prospects for blood-stage malaria vaccinesCharacterization of fine specificity of the immune response to a Plasmodium falciparum rhoptry neck protein, PfAARP.Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model.Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccinesStructure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibodyPulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4+ T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen.Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions.Influenza virosomes as vaccine adjuvant and carrier system.Recent advances in the molecular design of synthetic vaccines.Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.Antibody and T-cell responses associated with experimental human malaria infection or vaccination show limited relationships.Public health challenges and prospects for malaria control and elimination.Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05-09 antigen could be a Malaria Vaccine Candidate.Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults
P2860
Q21034112-3D63DB27-4C47-4D63-946D-BA04AA1AB26CQ28731894-0A3BDFD5-46EC-4F6F-9BE0-4608761C3642Q35048518-EF707A89-5D15-43A1-B1D5-B98DF62CDA45Q35898837-4A2EEBA2-B4BC-4E76-843D-ADAADFD242DCQ36396040-0F248CE4-E467-4253-9726-F3636A8D6F45Q36514771-52E4BAD7-D142-4BB3-9B62-D8BCCE57A7B8Q36644236-3EE49CEB-833A-4197-B186-54E2582B3E7DQ36690983-0990A14B-9137-4E69-8D77-6DC6DA7BECCDQ37025030-40D24BB1-19FF-4DA7-A0D9-07581C6C6E24Q37240166-4D4312D5-FE7E-4A28-8D41-780B9B450688Q37264651-096EF189-50F6-46F3-BE72-15295C6D4FFAQ37530299-EFCB62A0-58C7-4072-AA1F-EB1D092D76D0Q37699090-B4E0E07D-3341-465F-BAA7-E024920668B7Q37740679-5691E604-2B17-46D5-BF0D-FDA7BB3F09E0Q38059751-D3E48558-4FA1-46E2-AFD8-05B34307841AQ38124062-77B47B2C-F8A9-4F86-9E91-2ABD1CD67A61Q38639938-39660A7A-FB9D-405B-A8C7-838B86DEA45FQ39507822-667CD1D8-7CF9-48F4-906E-01B8A6416B26Q41620472-C054B7B3-C04C-4252-B19F-A51F2D0433EFQ43881419-B69C770B-D2A2-4E98-9F3E-FFD0930CFCE6Q47213886-09D42CEA-80FE-43BF-9DE5-F6B391474B96Q56342219-EA1A3A27-B754-4631-A1D3-AF52D149D813
P2860
Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Virosome-formulated Plasmodium ...... semi-immune adults & children
@ast
Virosome-formulated Plasmodium ...... semi-immune adults & children
@en
Virosome-formulated Plasmodium ...... semi-immune adults & children
@nl
type
label
Virosome-formulated Plasmodium ...... semi-immune adults & children
@ast
Virosome-formulated Plasmodium ...... semi-immune adults & children
@en
Virosome-formulated Plasmodium ...... semi-immune adults & children
@nl
prefLabel
Virosome-formulated Plasmodium ...... semi-immune adults & children
@ast
Virosome-formulated Plasmodium ...... semi-immune adults & children
@en
Virosome-formulated Plasmodium ...... semi-immune adults & children
@nl
P2093
P2860
P50
P3181
P1433
P1476
Virosome-formulated Plasmodium ...... semi-immune adults & children
@en
P2093
Claudia Daubenberger
Ester Barnabas Machunda
Maxmillian Mpina
Mwanajaa Shomari Abdallah
Nicole Westerfeld
Patrick Georges Cech
Rinaldo Zurbriggen
Sabine Alexandra Stoffel
Thomas Aebi
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0022273
P407
P577
2011-01-01T00:00:00Z